Yahoo Finance

Jazz Pharmaceuticals (JAZZ) Is Up 27.7% After Ziihera Phase 3 Success in HER2-Positive Gastric Cancer Trial – Has the Bull Case Changed?

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Benzinga.com

Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer

Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with ...
The Globe and Mail

Jazz Pharmaceuticals Announces Positive Phase 3 Trial Results

Jazz Pharmaceuticals ( (JAZZ)) has issued an announcement. On November 17, 2025, Jazz Pharmaceuticals announced positive results from the Phase 3 HERIZON-GEA-01 trial, which evaluated Ziihera ...
Pharm Exec

FDA Grants Priority Review to Jazz Pharmaceuticals’ Zanidatamab for Multiple Forms of HER-2 Positive Biliary Tract Cancer

Submission for the FDA approval of zanidatamab was based on promising data from the Phase IIb HERIZON-BTC-01 clinical trial in patients with previously treated, unresectable, locally advanced, or ...